Living Cell Technologies Ltd. (AU:1AI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Algorae Pharmaceuticals has announced promising preclinical results for its drug candidate AI-168, which showed significant cardioprotective effects, surpassing traditional beta blockers. The company is seeking patent protection for AI-168 after these successful studies, positioning the drug to potentially capture a share of the lucrative cardiovascular treatment market.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue